IMRIS has announced that it has obtained regulatory CE mark for integrating the next generation MRI core technology into the VISIUS surgical theatre allowing for sales and marketing in the European Union.
This newest imaging technology, based on the Siemens Aera 1.5T(tesla) and Skyra 3.0T MRI scanners, helps IMRIS deliver even better image quality, faster 3D image acquisition, and improved ease-of-use and workflow during surgical procedures using intraoperative MRI (iMRI). The company received United States Food and Drug Administration (FDA) approval for these advancements in February 2014.
“These high-field intraoperative scanner options will give a hospital’s clinical team state-of-the-art applications and image quality that increase productivity,” says IMRIS president and chief executive officer Jay D Miller. “We bring the latest and unequaled imaging technology into the operating room where it can make the most difference – during the surgery. More and more neurosurgical centres are using image guidance with VISIUS iMRI for an expanding list of conditions and procedures and adjunctive interventions beyond brain tumour resections, such as laser ablation for tumours and epilepsy using stereotactic tools, deep brain stimulation (DBS) and other minimally-invasive techniques that are designed to improve patient outcomes.”
Inside a VISIUS surgical theatre equipped with high-field iMRI, surgeons have on-demand access to real-time data and state-of-the-art imaging during the procedure as the scanner uniquely moves on ceiling-mounted rails.
